

1. World Health Organization 2025, *Obesity and overweight*, <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> accessed 24th May 2025.
2. Stiebahl, S 2025, *Obesity statistics*, <https://researchbriefings.files.parliament.uk/documents/SN03336/SN03336.pdf>.
3. Mahase, E 2024, 'GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment', *BMJ*, 386:q1645.
4. National Health Service 2023, *Obesity: Treatment*, <https://www.nhs.uk/conditions/obesity/treatment/> accessed 10th May 2025.
5. National Institute for Health and Care Excellence 2025, *Overweight and obesity management*, [www.nice.org.uk/guidance/ng246](http://www.nice.org.uk/guidance/ng246).
6. Arabyat, RM, B., NM, I., A-AS & and Alzoubi, KH 2020, 'Analysis of prevalence, risk factors, and potential costs of unnecessary drug therapy in patients with chronic diseases at the outpatient setting', *Expert Review of Pharmacoeconomics & Outcomes Research*, 20(1):125-132.
7. Elwyn, G, Frosch, D, Thomson, R, Joseph-Williams, N, Lloyd, A, Kinnersley, P, Cording, E, Tomson, D, Dodd, C, Rollnick, S, Edwards, A & Barry, M 2012, 'Shared Decision Making: A Model for Clinical Practice', *Journal of General Internal Medicine*, 27(10):1361-1367.
8. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, Shamseer, L, Tetzlaff, JM, Akl, EA, Brennan, SE, Chou, R, Glanville, J, Grimshaw, JM, Hróbjartsson, A, Lalu, MM, Li, T, Loder, EW, Mayo-Wilson, E, McDonald, S, McGuinness, LA, Stewart, LA, Thomas, J, Tricco, AC, Welch, VA, Whiting, P & Moher, D 2021, 'The PRISMA 2020 statement: an updated guideline for reporting systematic reviews', *BMJ*, 372:n71.
9. Eriksen, MB & Frandsen, TF 2018, 'The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review', *J Med Libr Assoc*, 106(4):420-431.
10. Veritas Health Innovation 2025, *Covidence systematic review software*, Melbourne, Australia, [www.covidence.org](http://www.covidence.org).
11. Critical Appraisal Skills Programme n.d., *CASP Checklist: For Randomised Controlled Trials (RCTs)*, <https://casp-uk.net/casp-tools-checklists/randomised-controlled-trial-rct-checklist/>.
12. Higgins, J, Savović, J, Page, MJ, Elbers, RG & Sterne, JA 2024, 'Chapter 8: Assessing risk of bias in a randomized trial', in J Higgins, J Thomas, J Chandler, M Cumpston, T Li, M Page & V Welch (eds), *Cochrane Handbook for Systematic Reviews of Interventions*, Cochrane.

13. Anyiam, O, Phillips, B, Quinn, K, Wilkinson, D, Smith, K, Atherton, P & Idris, I 2024, 'Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus', *Clinical Nutrition*, 43(8):1907-1913.
14. Bagherzadeh-Rahmani, B, Marzetti, E, Karami, E, Campbell, BI, Fakourian, A, Haghighi, AH, Mousavi, SH, Heinrich, KM, Brazzi, L, Jung, F, Baker, JS & Patel, DI 2024, 'Tirzepatide and exercise training in obesity', *Clinical Hemorheology and Microcirculation*, 87(4):465-480.
15. Khoo, J, Ho, M, Kam, S, Taneja, R, Koo, S, Soon, G, Hsiang, J, Law, N & Ang, T 2019, 'Comparing effects of liraglutide-induced weight loss versus lifestyle modification on liver fat content and plasma acylcarnitine levels in obese adults with non-alcoholic fatty liver disease', *Liver International*, 39:941-949.
16. Khoo, J, Hsiang, J, Taneja, R, Law, N-M & Ang, T-L 2017, 'Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial', *Diabetes, Obesity and Metabolism*, 19(12):1814-1817.
17. Lundgren, JR, Janus, C, Jensen, SBK, Juhl, CR, Olsen, LM, Christensen, RM, Svane, MS, Bandholm, T, Bojsen-Møller, KN, Blond, MB, Jensen, J-EB, Stallknecht, BM, Holst, JJ, Madsbad, S & Torekov, SS 2021, 'Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined', *New England Journal of Medicine*, 384(18):1719-1730
18. Silver, HJ, Olson, D, Mayfield, D, Wright, P, Nian, H, Mashayekhi, M, Koethe, JR, Niswender, KD, Luther, JM & Brown, NJ 2023, 'Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes', *Diabetes, Obesity and Metabolism*, 25(8):2340-2350.